BCS1L / Mitochondrial chaperone BCS1 · IHC design guide

Design Immunohistochemistry for BCS1L

Plan BCS1L paraffin-section IHC around the catalog antibody’s 1:50–1:200 dilution range (datasheet) and the reported cytoplasmic tissue pattern (HPA tissue IHC). Liver hepatocytes offer a high-staining control, while adipocytes were reported as unstained (HPA tissue IHC).

Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use

Immunohistochemistry protocol sheet for BCS1L (IHC for BCS1L): expected localisation Cytoplasmic tissue staining (HPA tissue IHC); inner membrane molecular site (UniProt), antibody A04885, validated IHC image, and IHC protocol steps — Printable **BCS1L** IHC protocol sheet — expected localisation Cytoplasmic tissue staining (HPA tissue IHC); inner membrane molecular site (UniProt), antibody A04885, controls and protocol steps. Open the full BCS1L IHC guide →

Navigate to: Protocols Staining pattern Controls Antibodies

BCS1L Immunohistochemistry Experimental Design Guide

Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.

Must know before staining

	Expected localisation	Cytoplasmic tissue staining (HPA tissue IHC); inner membrane molecular site (UniProt)
	Staining pattern	Widespread cytoplasmic staining across cell types (HPA tissue IHC)
	Antigen retrieval	Citrate pH 6.0 HIER, 95–98 °C, 20 min (rule: cytoplasmic / membrane antigen)
	Positive control ⓘ	Adrenal gland+4 more · see all
	Negative control ⓘ	Adipose tissue

Important caveats

Reasons your staining may differ from the expected pattern.

	Fixation	Keep paraffin-section fixation consistent across samples. (standard IHC practice; not target-specific)
	Caveat	Adipocytes may be unstained despite broad expression (HPA tissue IHC)
	Regulation	Ubiquitous expression; no regulator specified (UniProt)
	Isoform / epitope	No annotated isoforms; chain spans residues 2–419 (UniProt)

Section 1

Recommended BCS1L IHC & IF Protocols

Compare the catalog antibody’s IHC-P protocol with the published BCS1L protocol for formalin-fixed, paraffin-embedded FT and SOC tissues (PMC13039997).

Recommended immunohistochemistry (IHC-P) protocol parameters
Sample	Paraffin-embedded human stomach tissue; fixative not specified (datasheet A04885)
Fixation	Image fixative and duration unreported (datasheet A04885); verify before use.
Sectioning	4–5 µm sections on charged slides (standard)
Deparaffinisation	Xylene, graded ethanol series to water (standard)
Antigen retrieval	Heat-induced epitope retrieval in citrate buffer, pH 6.0, 20 min at 95–98 °C (standard rule: cytoplasmic / membrane antigen)
Peroxidase block	3% H2O2, 10 min, room temperature (standard)
Blocking	10% normal serum of the secondary host, 30 min, room temperature (standard)
Primary antibody	Rabbit anti-BCS1L, 1:50-1:200 (datasheet A04885)
Primary incubation	Overnight at 4 °C (standard)
Detection	HRP-polymer secondary, DAB chromogen 5–10 min (standard)
Counterstain	Hematoxylin, blue, dehydrate and mount (standard)
Expected result	BCS1L-positive staining in glandular cells of adrenal gland (HPA tissue IHC: High). HPA tissue profile: Ubiquitous cytoplasmic expression. No signal in the no-primary control.

💡Decision noteStart with citrate pH 6.0 retrieval at 95–98 °C for 20 min (page retrieval rule); the published workflow used microwave EDTA retrieval (PMC13039997).

Section 2

What Is the Expected BCS1L Staining Pattern?

BCS1L is an inner mitochondrial membrane protein with residues 33–419 facing the matrix (UniProt Q9Y276 topology). In paraffin section IHC, expect cytoplasmic staining in many cell types (HPA: ubiquitous cytoplasmic expression), including strong staining in hepatocytes and several glandular epithelia (HPA: High). HPA rates the tissue IHC pattern Supported, with medium consistency between staining and RNA expression (HPA: reliability description).

What am I looking at on my slide?
Strong cytoplasmic staining in hepatocytes or colon glandular cells, with cellular detail preserved.	This agrees with the reported High staining in those cells (HPA: liver and colon). A granular cytoplasmic appearance is compatible with mitochondrial residence (UniProt Q9Y276 subcellular location), although HPA tissue IHC describes the pattern only as cytoplasmic. Judge the compartment and cell identity together; intensity alone cannot establish specificity.
Predominantly nuclear or surface staining, with little discernible cytoplasmic signal.	That compartment conflicts with the reported cytoplasmic tissue pattern (HPA: tissue IHC) and inner mitochondrial membrane location (UniProt Q9Y276 topology). Treat it as a possible artefact until staining conditions and controls are reviewed. The supplied sources do not establish nuclear or surface BCS1L staining as an expected IHC result.
Strong staining in adipocytes, especially if the known-positive cells show little signal.	HPA reports BCS1L as Not detected in adipocytes (HPA: adipose tissue). Such a reversal raises concern for cross-reactivity or endogenous detection activity (general IHC practice). It is a comparison with the supplied HPA pattern, not proof that every adipocyte in every specimen must be negative.
Diffuse color across cells and tissue spaces, with no clear cytoplasmic boundaries.	This is difficult to score as BCS1L because HPA reports a cellular cytoplasmic pattern (HPA: tissue IHC). Excess antibody, incomplete blocking, or inadequate washing can produce diffuse background (general IHC practice). Compare a control without primary antibody and inspect whether the color follows tissue structure.
No staining in hepatocytes or another supplied High-staining cell population.	Absence in an expected positive population calls the run into question (HPA: High in hepatocytes and listed glandular cells). Review section integrity, retrieval, antibody application, and detection controls as general IHC practice. HPA's Supported rating has medium consistency with RNA data, so one negative specimen alone cannot settle biological absence (HPA: reliability description).

💡Expected BCS1L appearanceCall the IHC result consistent when defined cytoplasmic staining is evident in hepatocytes or supplied High-staining epithelia (HPA: liver and listed epithelia), with mitochondrial localization plausible from UniProt Q9Y276; predominantly nuclear, surface, or structureless diffuse color is a possible false-positive pattern (HPA: cytoplasmic tissue IHC; general IHC practice).

How each factor affects the staining
Where should the signal be assessed?	BCS1L spans the inner mitochondrial membrane once at residues 16–32, with residues 33–419 on the matrix side (UniProt Q9Y276 topology). This supports a cytoplasmic, mitochondria-compatible interpretation of IHC staining; tissue IHC does not resolve the membrane or establish an epitope position (HPA: cytoplasmic expression).
Which cells make useful pattern comparisons?	Hepatocytes and the supplied glandular and squamous epithelial populations are reported High, while adipocytes are Not detected and bone marrow hematopoietic cells are Low (HPA: tissue IHC). Use cell identity when comparing slides; ubiquitous expression and low RNA tissue specificity do not imply equal staining in every cell (UniProt Q9Y276 tissue specificity; HPA: RNA specificity).
How strong is the tissue IHC evidence?	Both listed antibodies, HPA037700 and HPA037701, have Supported IHC status (HPA: antibody validation). The overall tissue pattern is Supported with medium consistency between staining and RNA expression (HPA: reliability description). These labels support a reference pattern but do not independently prove the identity of every stained structure.
Does IF/ICC confirm the same compartment?	HPA's ICC-IF summary says mainly vesicles, with an additional mid-piece location; the vesicle assignment is Uncertain and the mid-piece assignment is Approved (HPA: subcellular ICC-IF). HPA037701 has Uncertain ICC status, while no ICC status is supplied for HPA037700 (HPA: antibody validation). Assess IF/ICC on its own guide page rather than treating these images as confirmation of mitochondrial IHC.
Do annotated variants or processing change the expected slide pattern?	The supplied UniProt record annotates no isoforms, signal peptide, propeptide, or glycosylation sites, and lists a chain from residues 2–419 (UniProt Q9Y276 processing). It therefore supplies no basis for predicting a separate secreted or cleaved staining compartment. These annotations also provide no target-specific fixation-sensitivity claim.

Why is my staining missing, weak or wrong?
Situation	Likely cause	Next action
The positive tissue is blank, including hepatocytes.	The result disagrees with High hepatocyte staining (HPA: liver); a failed IHC run remains possible (general IHC practice).	Check the positive-control section, primary antibody application, detection reagents, and counterstain. Review retrieval as a general IHC variable; no BCS1L-specific retrieval or fixation response is supplied.
Adipocytes stain as strongly as neighboring expected-positive cells.	HPA reports adipocytes as Not detected (HPA: adipose tissue). Cross-reactivity or endogenous detection activity is possible (general IHC practice).	Compare matched tissue morphology and a control without primary antibody. If color persists without primary, investigate the detection system and its blocking steps (general IHC practice).
The slide has mainly nuclear staining.	Nuclear dominance disagrees with cytoplasmic tissue IHC (HPA: tissue IHC) and mitochondrial inner membrane residence (UniProt Q9Y276).	Recheck cell boundaries and the counterstain, then compare a known-positive cytoplasmic control. Review antibody concentration and detection background as general IHC practice before interpreting the nuclear signal.
Brown color is widespread but lacks a recognizable cell pattern.	Diffuse background can follow excessive antibody, insufficient blocking, or incomplete washing (general IHC practice); it cannot establish the HPA cytoplasmic pattern.	Inspect the control without primary antibody, then optimize blocking, antibody concentration, and washes under the assay's general IHC workflow. Score only interpretable cellular staining.
Only weak staining appears in bone marrow hematopoietic cells.	Low staining is compatible with the supplied HPA observation for those cells (HPA: bone marrow).	Check hepatocytes or a supplied High-staining epithelial population in the same run (HPA: tissue IHC). Do not classify a run as failed solely because the bone marrow signal is weak.
An IF/ICC image looks vesicular while paraffin IHC looks cytoplasmic.	HPA reports vesicles as an Uncertain main ICC-IF location and cytoplasmic tissue IHC as Supported (HPA: subcellular and tissue IHC).	Keep the assay-specific observations distinct. Use the IF/ICC guide for its controls and interpretation; do not change the IHC compartment call on the basis of the uncertain vesicle assignment alone (HPA: ICC-IF location status).

Source: UniProt Q9Y276 Human Protein Atlas tissue Human Protein Atlas subcellular

Experiment evidence

IHC & IF images showing BCS1L staining

Immunohistochemistry of paraffin-embedded human stomach using BCS1L antibody at dilution of 1:100 .Perform microwave antigen retrieval with 10 mM PBS buffer pH 7.2 before commencing with IHC staining protocol.

A04885 · IHCImmunohistochemistry of paraffin-embedded human stomach using BCS1L antibody at dilution of 1:100 .Perform microwave antigen retrieval with

Immunohistochemistry of paraffin-embedded rat brain using BCS1L antibody at dilution of 1:100 .Perform microwave antigen retrieval with 10 mM PBS buffer pH 7.2 before commencing with IHC staining protocol.

A04885 · IHCImmunohistochemistry of paraffin-embedded rat brain using BCS1L antibody at dilution of 1:100 .Perform microwave antigen retrieval with 10 m

HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000074582-BCS1L/tissue/cerebral+cortex#imid_10730391

HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000074582-BCS1L/tissue/colon#imid_10730325

HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000074582-BCS1L/tissue/liver#imid_10730318

HPA · PancreasHuman Protein Atlas IHC, Pancreas. Source: https://www.proteinatlas.org/ENSG00000074582-BCS1L/tissue/pancreas#imid_10730277

HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA037701; green = BCS1L, blue = nucleus, red = microtubules.

← swipe / scroll for more images →

Real IHC / IF data behind the staining-pattern expectations in this section.

Sample controls for BCS1L IHC & IF

🧪Run colon first; its glandular cells should stain (HPA: High in colon glandular cells). Run adipose tissue as the negative comparison (HPA: Not detected in adipocytes); acellular areas on the colon slide should show only background (standard IHC practice), while other colon cell types should not be assumed negative (UniProt Q9Y276: ubiquitous).

Positive control tissue: Adrenal gland (Glandular cells, HPA High)

Negative control tissue: Adipose tissue (HPA Not detected)

ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show BCS1L in A-431, U-251MG, U2OS, Sperm, with annotated localisation: Vesicles (uncertain) (HPA subcellular).

Technical controls: Include a no-primary, secondary-only control; an isotype control matched to the primary antibody’s host species and immunoglobulin class, or host IgG for a polyclonal primary; and BCS1L-knockout material processed in parallel, or an immunizing-peptide block if the peptide is available (standard IHC controls). Block endogenous peroxidase and check inflammatory cells for nonspecific chromogen in colon sections (standard chromogenic IHC practice).

⚠️Feasibility: A target-specific fixation window or fixation effect is unreported, and the selected paraffin-section caption does not state its fixative (A04885 caption: fixative not stated). The reported IHC procedure uses microwave retrieval in 10 mM PBS, pH 7.2, with antibody at 1:100; this reports a retrieval step, not a demonstrated retrieval dependency (A04885 caption). There is no supplied evidence that frozen sections or IF are easier than paraffin IHC; assess colon mucus and inflammatory-cell staining as possible interpretation artefacts (standard IHC practice).

HPA tissue IHC evidence for BCS1L

Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Supported — Medium consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.

Positive expression · recommended positive controls

Tissue	Cell type	Level	Evidence	Source
Adrenal gland	Glandular cells	High	Protein (IHC)	HPA →
Appendix	Glandular cells	High	Protein (IHC)	HPA →
Colon	Glandular cells	High	Protein (IHC)	HPA →
Duodenum	Glandular cells	High	Protein (IHC)	HPA →
Esophagus	Squamous epithelial cells	High	Protein (IHC)	HPA →

Undetected expression · recommended negative controls

Tissue	Cell type	Level	Evidence	Source
Adipose tissue	Adipocytes	Not detected	Protein (IHC)	HPA →

Section 3

Advanced BCS1L IHC Tips

Troubleshoot BCS1L staining in paraffin sections by checking retrieval, compartmental pattern, controls, and scoring before interpreting differences in chromogenic signal.

How should I retrieve BCS1L in paraffin sections with weak staining?

Start with citrate buffer at pH 6.0 for heat-induced epitope retrieval at 95–98 °C for 20 min (page retrieval setting). Allow sections to cool in buffer, then compare a stained section with a no-primary control processed through the same chromogenic workflow (standard IHC practice). If staining remains weak, test microwave retrieval in 10 mM PBS at pH 7.2, the condition reported for catalog antibody A04885 at 1:100 on paraffin-embedded human stomach (A04885 tissue-IHC caption). Keep antibody concentration and detection conditions constant between retrieval trials so changes in signal can be attributed to retrieval (standard IHC practice).

Could fixation explain weak or uneven BCS1L staining?

Target-specific sensitivity of BCS1L staining to fixative type or fixation time is unknown from the supplied evidence; the selected paraffin-section caption does not state a fixative (A04885 tissue-IHC caption). Record the fixative, fixation duration, section thickness, and processing history for each specimen before comparing signal (standard IHC practice). If staining varies across batches, process matched control sections together and change only one preparation variable at a time (standard IHC practice). Compare intact central tissue with edges and damaged areas, because uneven preparation can complicate interpretation of chromogenic staining (standard IHC practice). Do not infer a BCS1L-specific fixation effect from its mitochondrial topology or tissue-expression profile (UniProt Q9Y276; HPA tissue IHC).

Where should convincing BCS1L IHC signal appear?

Evaluate BCS1L as a predominantly cytoplasmic stain in tissue sections, consistent with the reported tissue-IHC profile (HPA tissue IHC: ubiquitous cytoplasmic expression). Its annotated location is the mitochondrial inner membrane, with residues 16–32 spanning the membrane and residues 33–419 on the matrix side (UniProt Q9Y276 topology). Chromogenic signal may lack the resolution needed to assign individual mitochondrial membranes, so score the cellular pattern without claiming membrane-level localisation (standard IHC interpretation). Diffuse nuclear staining or staining confined to extracellular material warrants scrutiny against no-primary and tissue controls (standard IHC practice). HPA cell imaging also reports vesicles with uncertain localisation, so use that observation cautiously when interpreting puncta (HPA subcellular).

How can epitope location affect BCS1L staining after retrieval?

The supplied record lists 0 annotated isoforms, but the antibody epitope is not specified, so this evidence cannot establish which region retrieval exposes (UniProt Q9Y276; A04885 tissue-IHC caption). BCS1L has an inner-membrane segment at residues 16–32 and a matrix-facing region at residues 33–419 (UniProt Q9Y276 topology). It also lists a phosphotyrosine at residue 181; that annotation alone does not show that this antibody recognizes a modification-sensitive epitope (UniProt Q9Y276). When retrieval changes staining, compare matched sections under fixed antibody and detection conditions, and seek an epitope specification before assigning the change to topology or phosphorylation (standard IHC practice).

How should I assess BCS1L by IF alongside the IHC result?

Treat IF as a separate assay and assess whether its BCS1L pattern agrees with the mitochondrial inner-membrane annotation and the tissue-IHC cytoplasmic profile (UniProt Q9Y276; HPA tissue IHC). For multiplexing, pair BCS1L with a validated marker of the expected cell type and use single-stain controls to check channel bleed-through (standard IF practice). Select a fluorophore channel after measuring tissue autofluorescence, then keep exposure settings consistent across matched samples (standard IF practice). The antibody epitope is unspecified; if it lies on the matrix-facing side of residues 33–419, test permeabilisation conditions that permit access across mitochondrial membranes without assuming an IHC retrieval condition transfers to IF (UniProt Q9Y276 topology; standard IF practice).

How can I reduce diffuse brown background without losing BCS1L signal?

First compare the stained section with no-primary and detection-only controls to distinguish antibody-dependent signal from chromogen or detection background (standard IHC practice). For peroxidase-based detection, include a peroxidase block before DAB development and check whether endogenous activity persists in the control (standard chromogenic IHC practice). Titrate the primary antibody and blocking conditions on adjacent sections while keeping retrieval, incubation time, and DAB development consistent (standard IHC practice). The selected catalog-antibody caption reports 1:100 for paraffin-embedded human stomach after microwave retrieval in 10 mM PBS at pH 7.2; use that result as product-specific context, not a universal dilution (A04885 tissue-IHC caption).

What scoring method makes BCS1L IHC comparisons reproducible? ⚠ ANSWER MARKED FOR VERIFICATION

Define the cell population and analysis region before scoring, then apply the same segmentation and chromogen thresholds to all matched sections (standard IHC quantification practice). An H-score combines the percentage of cells in intensity categories and ranges from 0–300; alternatively, report percent positive cells with a stated threshold (standard IHC quantification practice). For spatial comparisons, measure positive-cell density per mm² of viable tissue or quantify DAB-positive area against the viable compartment (standard IHC quantification practice). Normalise to the number of eligible cells or viable tissue area, and record background from control sections because BCS1L tissue expression is broadly cytoplasmic (HPA tissue IHC; standard IHC quantification practice).

When is a strong BCS1L signal more likely artefact than true staining?

A plausible result shows cytoplasmic staining in the evaluated cells, consistent with the tissue-IHC profile, while the protein is annotated to the mitochondrial inner membrane (HPA tissue IHC; UniProt Q9Y276). Treat isolated nuclear or extracellular deposits as suspect, especially when they appear in no-primary controls or fail to follow cell boundaries (standard IHC interpretation). Compare section edges, folds, and necrotic regions with intact central tissue; local signal restricted to damaged areas should not drive a positive call (standard IHC practice). Persistent DAB signal after omitting primary antibody suggests endogenous enzyme or detection background, which should be resolved before interpreting differences between specimens (standard chromogenic IHC practice).

Boster reagents

Best BCS1L / Mitochondrial chaperone BCS1 IHC Antibodies

The anti-BCS1L antibody A04885 has IHC images from paraffin-embedded human stomach and rat brain; IF/ICC is listed for human, mouse, and rat without an IF image (catalog: A04885).

Real IHC data Immunohistochemistry of paraffin-embedded human stomach using BCS1L antibody at dilution of 1:100 .Perform microwave antigen retrieval with 10 mM PBS buffer pH 7.2 before commencing with IHC staining protocol.

Anti-Mitochondrial chaperone BCS1 BCS1L Antibody

Cat # A04885

View product →

A04885 has IHC images from paraffin-embedded human stomach and rat brain, each stained at 1:100 (A04885 IHC captions). IF/ICC is listed for A04885, but no IF image is supplied; mouse is listed as reactive without a supplied IHC image (catalog: A04885 applications, reactivity, image alts).

Which to pick: For tissue IHC, choose A04885: its own captions document paraffin sections and microwave antigen retrieval in 10 mM PBS at pH 7.2; the fixative is unreported (A04885 IHC captions). For IF/ICC, A04885 is the listed option at 1:50–1:200, though no IF image is supplied; its host is rabbit and clonality is unreported (catalog: A04885 applications, IF dilution, host, clone, IF image alts). For cross-species work, A04885 lists human, mouse, and rat reactivity, with supplied IHC images for human and rat samples (catalog: A04885 reactivity; A04885 IHC captions).

Each figure is that product's own IHC / IF validation image from its datasheet.

References

UniProt Consortium. UniProt entry Q9Y276 (BCS1_HUMAN, Mitochondrial chaperone BCS1).
Human Protein Atlas. BCS1L tissue IHC expression (reliability: Supported).
Human Protein Atlas. BCS1L subcellular location (ICC-IF): Mainly localized to vesicles. In addition localized to the mid piece..
Human Protein Atlas. BCS1L antibody validation summary (2 antibodies).
Quantitative proteomics analysis of altered protein expression in the placental villous tissue of early pregnancy loss using isobaric tandem mass tags. BioMed research international 2014 — PMC3971554.
Splice-switching of the oncogenic BCS1L isoform suppresses ovarian cancer progression by disrupting mitochondrial function. Cell death & disease 2026 — PMC13039997.
Respiratory chain complex III deficiency due to mutated BCS1L: a novel phenotype with encephalomyopathy, partially phenocopied in a Bcs1l mutant mouse model. Orphanet journal of rare diseases 2017 — PMC5399415.
PubMed PMID:9878253 — UniProt-cited evidence.
PubMed PMID:11528392 — UniProt-cited evidence.
PubMed PMID:12215968 — UniProt-cited evidence.